| Treatment outcomes of well‐differentiated high‐grade neuroendocrine tumors AJ Liu, BE Ueberroth, PW McGarrah, SA Buckner Petty, AT Kendi, J Starr, ... The oncologist 26 (5), 383-388, 2021 | 35 | 2021 |
| Temozolomide in grade 3 gastroenteropancreatic neuroendocrine neoplasms: a multicenter retrospective review DL Chan, EK Bergsland, JA Chan, R Gadgil, TR Halfdanarson, ... The Oncologist 26 (11), 950-955, 2021 | 32 | 2021 |
| Targeting cytochrome P450-dependent cancer cell mitochondria: cancer associated CYPs and where to find them Z Guo, V Johnson, J Barrera, M Porras, D Hinojosa, I Hernández, ... Cancer and Metastasis Reviews 37, 409-423, 2018 | 32 | 2018 |
| Src‐dependent phosphorylation of μ‐opioid receptor at Tyr336 modulates opiate withdrawal L Zhang, C Kibaly, YJ Wang, C Xu, KY Song, PW McGarrah, HH Loh, ... EMBO molecular medicine 9 (11), 1521-1536, 2017 | 22 | 2017 |
| Efficacy of second-line chemotherapy in extrapulmonary neuroendocrine carcinoma PW McGarrah, K Leventakos, TJ Hobday, JR Molina, HD Finnes, ... Pancreas 49 (4), 529-533, 2020 | 20 | 2020 |
| A review of theranostics: perspectives on emerging approaches and clinical advancements BJ Burkett, DJ Bartlett, PW McGarrah, AR Lewis, DR Johnson, ... Radiology: Imaging Cancer 5 (4), e220157, 2023 | 18 | 2023 |
| Renal neuroendocrine neoplasms: a single-center experience PW McGarrah, GFM Westin, TJ Hobday, JA Scales, JP Ingimarsson, ... Clinical genitourinary cancer 18 (4), e343-e349, 2020 | 18 | 2020 |
| Efficacy of checkpoint inhibitors in neuroendocrine neoplasms: mayo clinic experience JJ Gile, AJ Liu, PW McGarrah, RA Eiring, TJ Hobday, JS Starr, MB Sonbol, ... Pancreas 50 (4), 500-505, 2021 | 17 | 2021 |
| Efficacy of somatostatin analog (SSA) monotherapy for well-differentiated grade 3 (G3) gastroenteropancreatic neuroendocrine tumors (NETs). PW McGarrah, TJ Hobday, JS Starr, AT Kendi, RP Graham, MB Sonbol, ... Journal of Clinical Oncology 38 (4_suppl), 617-617, 2020 | 16 | 2020 |
| Temozolomide in grade III neuroendocrine neoplasms (G3 NENs): A multicenter retrospective review. D Chan, EK Bergsland, JA Chan, R Gadgil, TR Halfdanarson, ... Journal of Clinical Oncology 37 (4_suppl), 321-321, 2019 | 12 | 2019 |
| Urinary Neuroendocrine Neoplasms Treated in the “Modern Era”: A Multicenter Retrospective Review BK Le, P McGarrah, A Paciorek, A Mohamed, AB Apolo, DL Chan, ... Clinical Genitourinary Cancer 21 (3), 403-414. e5, 2023 | 3 | 2023 |
| Phase 1/2 trial of vesicular stomatitis virus expressing human interferon-β and NIS (VSV-IFNβ-NIS), with pembrolizumab, in patients with neuroendocrine carcinoma. PW McGarrah, S Naik, TR Halfdanarson, K Leventakos, KW Peng, ... Journal of Clinical Oncology 41 (4_suppl), TPS657-TPS657, 2023 | 3 | 2023 |
| Recurrent Tumefactive Central Nervous System Lesions Due to BRIP1-Related Fanconi Anemia N Nathoo, RH Gavrilova, JA Trejo-Lopez, PW McGarrah, RS Go, ... The neurologist 28 (5), 332-334, 2023 | 1 | 2023 |
| Baseline Quality of Life is a Strong and Independent Prognostic Factor for Overall Survival in Metastatic Colorectal Cancer P McGarrah, J Hubbard, PJ Novotny, ME Branda, DS Sargent, RF Morton, ... Cancer Control 30, 10732748231185047, 2023 | 1 | 2023 |
| A phase II study of pemetrexed and pembrolizumab in recurrent and/or metastatic salivary gland malignancies. KAR Price, NR Foster, HE Fuentes Bayne, C Fazer, P Savvides, Y Zhao, ... Journal of Clinical Oncology 40 (16_suppl), TPS6111-TPS6111, 2022 | 1 | 2022 |
| Neuroendocrine neoplasms of the oropharynx—a literature review L Maciejko, V Palacios, K Van Abel, T Halfdanarson, AV Chintakuntlawar, ... International Journal of Radiation Oncology, Biology, Physics 112 (5), e52-e53, 2022 | 1 | 2022 |
| Efficacy of checkpoint inhibitors in combination with chemotherapy in patients with high-grade extrapulmonary neuroendocrine carcinoma JJ Gile, PW McGarrah, K Leventakos, MB Sonbol, JS Starr, RA Eiring, ... PANCREAS 51 (3), E35-E35, 2022 | 1 | 2022 |
| Utilizing next-generation sequencing to characterize a case of acute myeloid leukemia with t (4; 12)(q12; p13) in the absence of ETV6/CHIC2 and ETV6/PDGFRA gene fusions A Koleilat, PW McGarrah, H Olteanu, DL Van Dyke, JB Smadbeck, ... Cancer Genetics 260, 1-5, 2022 | 1 | 2022 |
| Efficacy of somatostatin analogue (SSA) monotherapy for well-differentiated grade 3 (G3) gastroenteropancreatic neuroendocrine tumors (NETs) P McGarrah, A Liu, T Hobday, J Starr, A Kendi, R Graham, M Sonbol, ... JOURNAL OF NEUROENDOCRINOLOGY 33, 141-141, 2021 | 1 | 2021 |
| Efficacy of 2nd-line chemotherapy in patients with poorly differentiated, high grade extrapulmonary neuroendocrine carcinoma (PD NEC). PW McGarrah, K Leventakos, TJ Hobday, JR Molina, HD Finnes, ... Journal of Clinical Oncology 36 (15_suppl), e16162-e16162, 2018 | 1 | 2018 |
